Yuan Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuan Feng has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoli Lan
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 shared publications - Dawei Jiang
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
11 shared publications - Xiao Zhang
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 shared publications - Yongkang Gai
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 shared publications - Danzha Zheng
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 shared publications - Haiyang Yin
Jecho Institute, Shanghai, China
10 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (20) , eaec1692
Helper lipid-engineered extracellular vesicles enable PET imaging–guided pulmonary siRNA delivery to treat lung metastasis
Pulmonary diseases, including malignancies and chronic airway diseases, pose substantial global health challenges requiring advanced therapies. While extracellular vesicles (EVs) show promise as natural delivery vectors, their clinical application is limited by hepatic tropism. To date, no rational design for selectively lung-targeted EVs has been developed. Here, we modulate tumor cell–derived medium vesicles (TMVs) with cationic DOTAP lipids to alter their internal charges and tissue tropism. We accurately tracked the biodistribution of TMVs-DOTAP in vivo via highly sensitive positron emission tomography (PET) imaging, which clearly indicates their enhanced lung-targeting specificity. Furthermore, we engineered an EV-based siRNA delivery system (TMVs-DOTAP/siPD-L1), which effectively targets and silences PD-L1 in melanoma lung metastasis, leading to enhanced tumor immune responses. Mechanistic studies revealed the role of the protein corona in determining lung/liver tropism. This study provides a promising strategy for nucleic acid delivery and immunotherapy in pulmonary diseases.
- 15 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (20) , eaec1692
Open AccessHelper lipid-engineered extracellular vesicles enable PET imaging–guided pulmonary siRNA delivery to treat lung metastasis
Pulmonary diseases, including malignancies and chronic airway diseases, pose substantial global health challenges requiring advanced therapies. While extracellular vesicles (EVs) show promise as natural delivery vectors, their clinical application is limited by hepatic tropism. To date, no rational design for selectively lung-targeted EVs has been developed. Here, we modulate tumor cell–derived medium vesicles (TMVs) with cationic DOTAP lipids to alter their internal charges and tissue tropism. We accurately tracked the biodistribution of TMVs-DOTAP in vivo via highly sensitive positron emission tomography (PET) imaging, which clearly indicates their enhanced lung-targeting specificity. Furthermore, we engineered an EV-based siRNA delivery system (TMVs-DOTAP/siPD-L1), which effectively targets and silences PD-L1 in melanoma lung metastasis, leading to enhanced tumor immune responses. Mechanistic studies revealed the role of the protein corona in determining lung/liver tropism. This study provides a promising strategy for nucleic acid delivery and immunotherapy in pulmonary diseases.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S1. Summary of study design and imaging workflow.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S1. Summary of study design and imaging workflow.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Purpose:This study aims to develop and evaluate a novel glypican-3 (GPC3)–targeted, single-chain variable fragment–based PET radiotracer for noninvasive assessment of GPC3 expression and precise diagnosis of hepatocellular carcinoma (HCC) in both preclinical models and a first-in-human clinical study.Experimental Design:The novel anti-GPC3 single-chain variable fragment, namely, XH-06, was labeled with gallium-68 to obtain [68Ga]Ga-XH-06. Cell uptake assays, small-animal PET imaging, and biodistribution studies were performed to evaluate its targeting ability. In the first-in-human study, eight patients with suspected HCC underwent [68Ga]Ga-XH-06 PET/MRI. Radiotracer uptake in tumors and normal tissues was quantified, and tumor-to-blood ratios and tumor-to-liver ratios were calculated.Results:[68Ga]Ga-XH-06 was synthesized with high radiochemical purity and exhibited specific uptake and efficient internalization in GPC3-positive cells. In subcutaneous and orthotopic animal models, [68Ga]Ga-XH-06 effectively visualized HCC tumors. Eight patients underwent [68Ga]Ga-XH-06 PET/MRI scans, and no adverse events were observed. The radiotracer successfully detected HCC lesions, including subcentimeter tumors, with high imaging contrast. Among seven patients with HCC, the median maximum standardized uptake value of the lesions was 16.9 (range, 8.2–51.8), the median tumor-to-liver ratio was 6.2 (range, 2.8–24.7), and the median tumor-to-blood ratio was 16.6 (range, 3.0–57.6) at 2.5 hours after injection.Conclusions:[68Ga]Ga-XH-06 is clinically promising for detecting GPC3-positive HCC with a favorable safety profile. Further investigation is warranted to validate the clinical value of GPC3-targeted PET imaging in HCC management.See related commentary by Seo and Flavell, p. 445
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Purpose:This study aims to develop and evaluate a novel glypican-3 (GPC3)–targeted, single-chain variable fragment–based PET radiotracer for noninvasive assessment of GPC3 expression and precise diagnosis of hepatocellular carcinoma (HCC) in both preclinical models and a first-in-human clinical study.Experimental Design:The novel anti-GPC3 single-chain variable fragment, namely, XH-06, was labeled with gallium-68 to obtain [68Ga]Ga-XH-06. Cell uptake assays, small-animal PET imaging, and biodistribution studies were performed to evaluate its targeting ability. In the first-in-human study, eight patients with suspected HCC underwent [68Ga]Ga-XH-06 PET/MRI. Radiotracer uptake in tumors and normal tissues was quantified, and tumor-to-blood ratios and tumor-to-liver ratios were calculated.Results:[68Ga]Ga-XH-06 was synthesized with high radiochemical purity and exhibited specific uptake and efficient internalization in GPC3-positive cells. In subcutaneous and orthotopic animal models, [68Ga]Ga-XH-06 effectively visualized HCC tumors. Eight patients underwent [68Ga]Ga-XH-06 PET/MRI scans, and no adverse events were observed. The radiotracer successfully detected HCC lesions, including subcentimeter tumors, with high imaging contrast. Among seven patients with HCC, the median maximum standardized uptake value of the lesions was 16.9 (range, 8.2–51.8), the median tumor-to-liver ratio was 6.2 (range, 2.8–24.7), and the median tumor-to-blood ratio was 16.6 (range, 3.0–57.6) at 2.5 hours after injection.Conclusions:[68Ga]Ga-XH-06 is clinically promising for detecting GPC3-positive HCC with a favorable safety profile. Further investigation is warranted to validate the clinical value of GPC3-targeted PET imaging in HCC management.See related commentary by Seo and Flavell, p. 445
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S6. Quantitative ROI data in [68Ga]Ga-XH-06 immunoPET imaging of Hep3B orthotopic xenograft models.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S6. Quantitative ROI data in [68Ga]Ga-XH-06 immunoPET imaging of Hep3B orthotopic xenograft models.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Table S1. Kinetic parameters of the interaction between anti-GPC3 scFv (XH-06) and NOTA-XH-06 with human GPC3 protein determined by biolayer interferometry.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Table S1. Kinetic parameters of the interaction between anti-GPC3 scFv (XH-06) and NOTA-XH-06 with human GPC3 protein determined by biolayer interferometry.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S2. Sample purity determination using size exclusion-high-performance liquid chromatography. The purity of anti-GPC3 scFv (XH-06) was 100%.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S2. Sample purity determination using size exclusion-high-performance liquid chromatography. The purity of anti-GPC3 scFv (XH-06) was 100%.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Table S2. Mean organ absorbed dose coefficients and whole-body effective dose for [68Ga]Ga-XH-06 in three healthy volunteers.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Table S2. Mean organ absorbed dose coefficients and whole-body effective dose for [68Ga]Ga-XH-06 in three healthy volunteers.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S3. Quadrupole time-of-flight spectra of anti-GPC3 scFv (XH-06). The mass spectrum showed that the molecular weight of anti-GPC3 scFv was 26741 Da.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S3. Quadrupole time-of-flight spectra of anti-GPC3 scFv (XH-06). The mass spectrum showed that the molecular weight of anti-GPC3 scFv was 26741 Da.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S4. Comparison of quantitative region-of-interest (ROI) data in [68Ga]Ga-XH-06 immunoPET imaging of Hep3B and SK-HEP-1 subcutaneous xenograft models.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S4. Comparison of quantitative region-of-interest (ROI) data in [68Ga]Ga-XH-06 immunoPET imaging of Hep3B and SK-HEP-1 subcutaneous xenograft models.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S5. Hematoxylin and eosin (H&E) staining and GPC3 immunohistochemistry (IHC) of the resected subcutaneous xenografts.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S5. Hematoxylin and eosin (H&E) staining and GPC3 immunohistochemistry (IHC) of the resected subcutaneous xenografts.